Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
On February 7, 2023, Clarivate Plc (NYSE: CLVT) announced that it will release its financial results for the fourth quarter and full year 2022 on March 1, 2023, before market opening. Detailed financial information will be available on their investor website. A conference call and webcast will occur on the same day at 9:00 AM Eastern Time to discuss the results. Interested participants can access the live audio broadcast or join through the webcast link provided. Additionally, an audio replay will be available after the call until March 15, 2023.
Clarivate Plc (NYSE:CLVT) released a special investigation by BioWorld, examining the evolving understanding of obesity and the impact of new weight loss drugs. With an expected one billion people facing obesity by 2030, novel therapeutics, including GLP-1R agonists, offer promising alternatives to traditional weight loss methods. The report discusses the cultural complexities surrounding obesity, the limitations of using weight as a health indicator, and highlights that fitness may be more closely associated with health than weight itself. The findings suggest a shift in the medical community's perception of weight loss and overall health.
Clarivate Plc (NYSE:CLVT) recently released its 2023 Drugs to Watch report, marking its tenth anniversary. The report predicts over 70 drugs that may transform treatment for various conditions, including HIV and Parkinson's disease. Notably, 15 late-stage experimental treatments are expected to surpass $1 billion in annual sales within five years. The report also highlights promising developments in Mainland China, especially in oncology, with nine drugs forecasted to reach blockbuster status by 2030, supported by healthcare reforms under Healthy China 2030.
On January 3, 2023, Clarivate Plc (NYSE: CLVT) collaborated with the Chinese Academy of Sciences to release the 'Research Fronts 2022' report, detailing 165 significant research areas in sciences and social sciences. The report identifies 110 'hot' and 55 'emerging' fronts, with over a third related to COVID-19, focusing on topics like vaccine effectiveness. Utilizing the Essential Science Indicators database, the report provides insights into scientific trends, showcasing the US as the leader in research, while highlighting a narrowing gap with China.
Clarivate (NYSE: CLVT) announced the adoption of a Tax Benefits Preservation Plan to safeguard its U.S. net operating loss carryforwards exceeding $1 billion as of September 30, 2022. This plan aims to prevent an 'ownership change' that could limit its ability to utilize these tax benefits. The plan will expire on October 31, 2023, unless terminated earlier. Shareholders will receive one preferred share purchase right for each ordinary share, activating if any party acquires 4.9% or more of shares. The plan is similar to those by other companies with significant NOLs.
Clarivate Plc (NYSE: CLVT) announced a reduction in its Board of Directors from 14 to 11 members, with the resignation of directors Balakrishnan S. Iyer, Kosty Gilis, and Roxane White. This move aims to enhance corporate governance, with 10 of the 11 remaining directors being independent and 45% being female or racially diverse. Board Chair Andrew Snyder emphasized that a smaller board will improve decision-making efficiency and focus on long-term growth and shareholder value.
Clarivate Plc (NYSE: CLVT) announced on December 6, 2022, the integration of linked specialty pharmacy claims data into its real-world data solutions. This new U.S. dataset enhances the company's offerings by providing insights into high-cost medications and the treatment journeys of patients with chronic and rare diseases. Specialty drugs comprise over 20% of the market in these areas. The dataset covers more than 500 specialty drugs and is updated weekly, enabling robust analytics and improved patient outcome strategies.
Clarivate Plc (NYSE: CLVT), a leader in providing insights to enhance innovation, announced that CEO Jonathan Gear and CFO Jonathan Collins will present at the Barclays Global Technology, Media, and Telecommunications Conference on December 7, 2022, at 10:25 AM PT (1:25 PM ET). Attendees can access the live webcast here, and it will be available for replay. Clarivate aims to assist customers in transforming innovations into real-world solutions.
Clarivate Plc (NYSE:CLVT) has launched its annual report, The Annual G20 Scorecard – Research Performance 2022, showcasing the research performance of G20 nations. Published by the Institute for Scientific Information, the report is timed with the G20 Summit in Bali. Key findings reveal that Australia maintains the highest international impact, while China's output has tripled. Saudi Arabia sees significant international collaboration, and South Korea leads in research expenditure. The UK and US demonstrate strong research impacts, with a notable focus on domestic and collaborative work.
On November 16, 2022, Clarivate Plc (NYSE: CLVT) announced a strategic partnership with IPwe Inc. to lead the digital transformation of intellectual property through advanced blockchain technology and AI. This collaboration aims to combine Clarivate's patent data with IPwe's Smart Intangible Asset Management platform, enhancing the validation and management of patent portfolios. By tokenizing patents, IPwe seeks to improve transparency and reduce transaction friction in the IP market. This partnership is expected to provide customers with a data-driven approach to managing intangible assets.